These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33651587)

  • 1. Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.
    Patel NC; Feng B; Hou X; West MA; Trapa PE; Sciabola S; Verhoest P; Liras JL; Maurer TS; Wager TT
    ACS Chem Neurosci; 2021 Mar; 12(6):1007-1017. PubMed ID: 33651587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
    Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
    Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
    Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
    J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
    Gupta M; Feng J; Bhisetti G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods to optimize CNS exposure of drug candidates.
    Patel NC
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127503. PubMed ID: 32853684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration.
    Jiang L; Kumar S; Nuechterlein M; Reyes M; Tran D; Cabebe C; Chiang P; Reynolds J; Carrier S; Sun Y; Eddershaw P; Hay T; Chen W; Feng B
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00932. PubMed ID: 35156331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
    Sato S; Tohyama K; Kosugi Y
    Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
    Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
    J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
    Huang L; Wells MC; Zhao Z
    Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
    Li Y; Wu Q; Li C; Liu L; Du K; Shen J; Wu Y; Zhao X; Zhao M; Bao L; Gao J; Keep RF; Xiang J
    PLoS One; 2016; 11(6):e0157576. PubMed ID: 27300692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
    Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved In Vitro-In Vivo Correlation by Using the Unbound-Fraction-Adjusted IC
    Imai S; Arai T; Yamada T; Niwa M
    Pharm Res; 2020 Oct; 37(12):230. PubMed ID: 33123823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
    Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
    Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.